Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Archive Search

Pages

256583 items
9:18 PM, May 23, 2018  |  BC Extra | Financial News

Scholar Rock raises $75M in IPO

Scholar Rock Holding Corp. (NASDAQ:SRRK) raised $75 million through the sale of 5.4 million shares at $14 in an IPO underwritten by Jefferies, Cowen, BMO Capital Markets and Wedbush PacGrow. Scholar Rock priced the offering at...
9:13 PM, May 23, 2018  |  BC Extra | Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced the offering at the...
4:47 PM, May 23, 2018  |  BC Innovations | Translation in Brief

Toward Tailored Chemo

A group at UCSF is bringing precision medicine to chemotherapies, with a predictive model for drug responses based on single gene deletions. Despite advances in immuno-oncology and targeted therapies, nearly 95% of cancer patients receive chemotherapy...
4:14 PM, May 23, 2018  |  BC Extra | Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19 from a pair of...
4:09 PM, May 23, 2018  |  BC Extra | Company News

Management Tracks: Lilly, LogicBio

Eli Lilly and Co. (NYSE:LLY) said Lilly SVP and Lilly Oncology President Sue Mahony will retire at the end of August. The pharma is searching for candidates to succeed Mahony. Gene editing company LogicBio Therapeutics Inc....
3:45 PM, May 23, 2018  |  BC Extra | Clinical News

Clementia falls on Phase II data for rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) lost $4.05 (21%) to $14.85 on Wednesday after reporting data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized...
3:34 PM, May 23, 2018  |  BC Extra | Company News

Takeda divests stake in Chinese JV

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on Wednesday that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a strategic...
2:45 PM, May 23, 2018  |  BC Extra | Financial News

Gene, cell therapy fund-raising set to outpace 2017 total

Gene and cell therapy companies have raised $2.3 billion in equity in 2018 as of the end of last week, according to BioCentury’s BCIQ database. The figure is more than half of the $4.5 billion...
2:30 PM, May 23, 2018  |  BC Extra | Company News

Vifor Fresenius to commercialize Cara’s Korsuva in international markets

Cara Therapeutics Inc. (NASDAQ:CARA) gained $4.96 (43%) to $16.56 on Wednesday after Vifor Fresenius Medical Care Renal Pharma Ltd. acquired rights to commercialize Korsuva difelikefalin (IV CR845) to treat chronic kidney disease-associated pruritus in dialysis...
2:16 PM, May 23, 2018  |  BC Extra | Financial News

Kronos raises seed round, names Bischofberger CEO

Cancer company Kronos Bio Inc. (Cambridge, Mass.) raised $18 million in seed financing Wednesday and hired Norbert Bischofberger as president and CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until...

Pages